Correction to: Prostate Cancer and Prostatic Diseases https://doi.org/10.1038/s41391-023-00675-1, published online 16 May 2023
The final sentence in the Results section of the abstract should read:
At 2.5 years, patients with low-risk EPI scores from both arms had less HGPC than high-risk EPI score patients (7.9% vs 27.3%, p < 0.001) and the EPI arm found 21.8% more HGPC than the SOC arm.
Instead, the final sentence in the Results section of the abstract currently reads:
At 2.5 years, patients with low-risk EPI scores from both arms had less HGPC than high-risk EPI score patients (7.9% vs 26.8%, p < 0.001) and the EPI arm found 18% more HGPC than the SOC arm.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Tutrone, R., Lowentritt, B., Neuman, B. et al. Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis. Prostate Cancer Prostatic Dis 27, 161 (2024). https://doi.org/10.1038/s41391-023-00681-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-023-00681-3
